Leadership Changes, Financial Results, Dividends, Stock Performance Update, and Recognitions - Research Report on Teva, Vertex, Zoetis, Humana, and Community Health Systems PR Newswire NEW YORK, November 4, 2013 NEW YORK, November 4, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Teva Pharmaceutical Industries Ltd. (ADR) (NYSE: TEVA), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Zoetis Inc. (NYSE: ZTS), Humana Inc. (NYSE: HUM), and Community Health Systems Inc. (NYSE: CYH). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Teva Pharmaceutical Industries Ltd. (ADR) Research Report On October 30, 2013, Teva Pharmaceutical Industries Ltd. (ADR) (Teva) announced that the Company's Board of Directors has approved Dr. Jeremy Levin's decision to step down from the role of President and CEO of the Company. Teva added that its Board of Directors has asked Eyal Desheh, Teva's Executive Vice President and CFO, to step in as the new President and CEO of Teva, on an interim basis, with immediate effect, until it finds a permanent successor for the role. Dr. Phillip Frost, Chairman of the Board, said, "On behalf of the entire Board of Directors, I would like to thank Dr. Jeremy Levin for his meaningful contribution to Teva during the last two years. The Board and management team are fully committed to the implementation of Teva's strategy, including the development of new compounds, making strategic acquisitions, forming joint ventures and the planned acceleration of the Company's cost reduction program." The Full Research Report on Teva Pharmaceutical Industries Ltd. (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e3a3_TEVA] Vertex Pharmaceuticals Incorporated Research Report On October 29, 2013, Vertex Pharmaceuticals Incorporated (Vertex) reported its Q3 2013 financial results. The Company's total revenues declined 34.0% YoY to $221.7 million during the quarter. Net loss attributable to Vertex was $124.1 million or $0.54 per diluted share, in Q3 2013, compared to net loss attributable to Vertex of $57.5 million or $0.27 per diluted share, in Q3 2012. Jeffrey Leiden, M.D., Ph.D., Chairman, President and CEO of Vertex, said, "Our business is at a unique point in its evolution. We have a tremendous opportunity ahead of us to further transform the treatment of cystic fibrosis, which continues to be the company's highest priority development program. Following the continued decline in the number of people starting treatment with INCIVEK, we today took the difficult step to reduce our workforce supporting this medicine, enabling us to focus our investment on key programs in cystic fibrosis and other diseases to position the company for future growth." The Full Research Report on Vertex Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e696_VRTX] Zoetis Inc. Research Report On October 30, 2013, Zoetis Inc.'s (Zoetis) stock rose 0.09%, ending the day at $32.06. Over the previous three trading sessions, shares of Zoetis declined 1.26% compared to the S&P 500, which gained 0.20% during the same period. The Full Research Report on Zoetis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7e25_ZTS] Humana Inc. Research Report On October 30, 2013, Humana Inc. (Humana) announced that the Company's Board of Directors has declared a cash dividend of $0.27 per share, which is payable on January 31, 2014 to stockholders of record as of the close of business on December 31, 2013. The Full Research Report on Humana Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/496b_HUM] Community Health Systems Inc. Research Report On October 30, 2013, Community Health Systems Inc. (Community Health) announced that 63 of the Company's affiliated hospitals have been recognized as Top Performers on Key Quality Measures by The Joint Commission, a leading accrediting agency for healthcare organizations. The Company said that of the 63 Community Health's affiliate hospitals that were recognized in 2013, 25 have appeared on The Joint Commission's Top Performers list for three years. Commenting on the news, Wayne T. Smith, Chairman, President and CEO of Community Health, said, "This recognition underscores our organization's very strong commitment to quality and patient safety, and demonstrates that physicians, nurses and other caregivers in our affiliated hospitals remain diligent in their use of evidence-based practices that can lead to better outcomes. We applaud the efforts of the hospitals that achieved this distinction and especially commend those that have sustained such a high level of clinical excellence over the years." The Full Research Report on Community Health Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7587_CYH] EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.analystscorner.com SOURCE Analysts' Corner Contact: Joe Thomas; +1-310-496-8071 (North America)
Leadership Changes, Financial Results, Dividends, Stock Performance Update, and Recognitions - Research Report on Teva, Vertex,
Press spacebar to pause and continue. Press esc to stop.